Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.




BENLYSTA Gateway is available through BENLYSTA Cares. BENLYSTA Gateway helps patients and healthcare professionals understand authorization*, access, distribution, and reimbursement for BENLYSTA.

1-877-4-BENLYSTA (1-877-423-6597)
Monday-Friday, 8 AM to 8 PM, ET

Select option 1 for BENLYSTA Gateway


BENLYSTA is available through a variety of options


BENLYSTA Gateway can complete a patient-specific benefits investigation with the patient's payer and provide PA research and support

For benefits investigation, BENLYSTA Gateway can:

  • Contact insurance companies to obtain specific coverage information
  • Determine whether payer requires prior authorization
  • Determine estimated patient out-of-pocket responsibility

Once BENLYSTA Gateway completes a benefit verification, you and your patient will receive a Summary of Benefits that will review the patient's coverage.

Please note that investigations do not guarantee a result, and it is the provider's responsibility to check with the payer. The patient's payer is the most accurate source of information about the patient's coverage.

For PA research and support, BENLYSTA Gateway can:

  • Research plan requirements
  • Outline steps required for obtaining a PA from the patient’s plan
  • Obtain unique and plan-specific PA forms (where applicable)

BENLYSTA Gateway can also follow up with the plan to help determine the status of the PA submission (if requested).

Remember, BENLYSTA Gateway cannot complete PA forms or submit related information to plans. Instead, it is the responsibility of the office and prescribing physician to provide the plan with patient-specific clinical documentation.


BENLYSTA Gateway can evaluate eligibility for the BENLYSTA Co-pay Program

Approved patients may pay as little as $0 for BENLYSTA

Who may be eligible?

Your patients may be eligible for the Program if they:

  • Have a commercial medical or prescription insurance plan
  • Are not insured
  • Are a resident of the US (including the District of Columbia, Puerto Rico, and the US Virgin Islands)

Who is not eligible?

Your patients are not eligible for the Program if they are:

  • Eligible for Medicare or have a state- or federal government-funded medical or prescription insurance plan such as Medicare, Medicaid, VA, or TRICARE
  • Age 65 or older (patients are considered eligible for Medicare and therefore not eligible for the Co-pay Program)
  • Enrolled in a commercial health plan that does not permit the use of co-pay assistance programs

BENLYSTA Gateway can help eligible uninsured and some Medicare patients who meet eligibility requirements obtain access to BENLYSTA free of charge through GSK's Patient Assistance Program.

Learn more about the Co-pay Program

BENLYSTA Gateway can also provide general information about coverage and out-of-pocket costs through completion of a benefit investigation on behalf of the patient (see section above).

*BENLYSTA Gateway CANNOT complete prior authorization forms or submit related information directly to Payers on behalf of physician.

The BENLYSTA Co-pay Program helps eligible approved patients with their out-of-pocket costs for BENLYSTA up to $15,000 for 12 months. If approved, patients could pay as little as $0 for BENLYSTA. Patients in Government funded programs (eg, Medicare,Medicaid,VA, or TriCare), are not eligible for the BENLYSTA Co-pay Program. Patients in Government funded programs (eg, Medicare, Medicaid, VA, or TriCare), are not eligible for the BENLYSTA Co-pay Program. Medicare eligible patients who are enrolled in certain retiree drug benefit plans are also ineligible for the Co-pay program (Most patients become eligible for Medicare when they reach age 65). Patients must submit an Enrollment Form or complete eligibility check online at benlystacopayprogram.com so their eligibility can be determined. Click here for full Program Terms & Conditions.


BENLYSTA is indicated for patients aged ≥5 years with active, autoantibody-positive systemic lupus erythematosus (SLE) who receive standard therapy. The subcutaneous (SC) formulation is approved for patients aged ≥18 years. BENLYSTA is not indicated or recommended in patients with severe active lupus nephritis, or severe active central nervous system lupus, or in combination with other biologics or intravenous cyclophosphamide.



Previous anaphylaxis with BENLYSTA.



Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA. The incidence of serious infections was similar in patients receiving BENLYSTA versus placebo, whereas fatal infections occurred more frequently with BENLYSTA. The most frequent serious infections in adults treated with BENLYSTA IV included pneumonia, urinary tract infection, cellulitis, and bronchitis. Use caution in patients with severe or chronic infections, and consider interrupting therapy in patients with a new infection.

Progressive Multifocal Leukoencephalopathy (PML): Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA. If PML is confirmed, consider stopping immunosuppressant therapy, including BENLYSTA.

Hypersensitivity Reactions (including Anaphylaxis): Acute hypersensitivity reactions, including anaphylaxis (eg, hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea) and death, have been reported, including in patients who have previously tolerated BENLYSTA. Generally, reactions occurred within hours of the infusion but may occur later. Non-acute hypersensitivity reactions (eg, rash, nausea, fatigue, myalgia, headache, and facial edema) typically occurred up to a week after infusion. Patients with a history of multiple drug allergies or significant hypersensitivity may be at increased risk. With BENLYSTA SC, systemic hypersensitivity reactions were similar to those in IV trials.

Healthcare providers (HCPs) should monitor patients during and after IV administration and be prepared to manage anaphylaxis; discontinue immediately in the event of a serious reaction. Premedication may mitigate or mask a hypersensitivity response. Advise patients about hypersensitivity symptoms and instruct them to seek immediate medical care if a reaction occurs.

Infusion Reactions: Serious infusion reactions (eg, bradycardia, myalgia, headache, rash, urticaria, and hypotension) were reported in adults. HCPs should monitor patients and manage reactions if they occur. Premedication may mitigate or mask a reaction. If an infusion reaction develops, slow or interrupt the infusion.

Depression and Suicidality: In adult trials, psychiatric events reported more frequently with BENLYSTA IV related primarily to depression-related events, insomnia, and anxiety; serious psychiatric events included serious depression and suicidality, including 2 completed suicides. No serious depression-related events or suicides were reported in the BENLYSTA SC trial. Before adding BENLYSTA, assess patients’ risk of depression and suicide and monitor them during treatment. Instruct patients/caregivers to contact their HCP if they experience new/worsening depression, suicidal thoughts, or other mood changes.

Malignancy: The impact of BENLYSTA on the development of malignancies is unknown; its mechanism of action could increase the risk for malignancies.

Immunization: Live vaccines should not be given for 30 days before or concurrently with BENLYSTA as clinical safety has not been established.

Use With Biologic Therapies or IV Cyclophosphamide: BENLYSTA has not been studied and is not recommended in combination with other biologic therapies, including B-cell targeted therapies, or IV cyclophosphamide.


The most common serious adverse reactions in adults were serious infections: BENLYSTA IV 6.0% (placebo 5.2%). Fatal infections occurred in 0.3% of patients receiving BENLYSTA and in 0.1% of patients receiving placebo. Adverse reactions occurring in ≥3% of adults and ≥1% more than placebo: nausea 15% (12%); diarrhea 12% (9%); pyrexia 10% (8%); nasopharyngitis 9% (7%); bronchitis 9% (5%); insomnia 7% (5%); pain in extremity 6% (4%); depression 5% (4%); migraine 5% (4%); pharyngitis 5% (3%); cystitis 4% (3%); leukopenia 4% (2%); viral gastroenteritis 3% (1%).

Adverse reactions in pediatric patients aged ≥5 years receiving BENLYSTA IV were consistent with those observed in adults.

The safety profile observed for BENLYSTA SC in adults was consistent with the known safety profile of BENLYSTA IV with the exception of local injection site reactions.


Pregnancy: There are insufficient data in pregnant women to establish whether there is drug-associated risk for major birth defects or miscarriage. After a risk/benefit assessment, if prevention is warranted, women of childbearing potential should use contraception during treatment and for ≥4 months after the final treatment.

Pregnancy Registry: HCPs are encouraged to register patients and pregnant women are encouraged to enroll themselves by calling 1-877-681-6296.

Lactation: No information is available on the presence of belimumab in human milk, the effects on the breastfed infant, or the effects on milk production. Consider developmental and health benefits of breastfeeding with the mother’s clinical need for BENLYSTA and any potential adverse effects on the breastfed child or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness have not been established for BENLYSTA IV in patients <5 years of age and for BENLYSTA SC in patients <18 years of age.

Please see full Prescribing Information and Medication Guide for BENLYSTA.

All trademarks are the property of their respective owners.